...
首页> 外文期刊>Pediatrics Neonatology >SCID/NOD mice model for 5-FU induced intestinal mucositis: Safety and effects of probiotics as therapy
【24h】

SCID/NOD mice model for 5-FU induced intestinal mucositis: Safety and effects of probiotics as therapy

机译:SCID / NOD小鼠5-FU诱发的肠粘膜炎的模型:益生菌作为治疗的安全性和作用

获取原文
           

摘要

Background For chemotherapy patients, intestinal mucositis is a frequent complication. Previously, we evaluated the beneficial effect of oral probiotics in 5-Fluorouracil (5-FU) induced mucositis in BALB/c mice. Here, we used SCID/NOD mice instead to simulate the immunodeficiency of chemotherapy patients: first, to evaluate the safety of probiotic supplementation and second, to determine the probiotic effect in response to 5-FU intestinal mucositis. Methods Thirty-six SCID/NOD mice were injected with saline (three control groups) or 5-FU (three experimental groups) intraperitoneally daily for five days. Mice were given either oral saline daily, probiotic suspension of Lactobacillus casei variety rhamnosus (Lcr35, Antibiophilus?, France) or Lactobacillus acidophilus and Bifidobacterium bifidum (LaBi, Infloran?, Italy). Blood, liver, spleen, and lymph node tissue samples were evaluated for probiotic translocation via culture and Q-PCR. Weight change, diarrhea score, jejunal villus height (VH) and crypt depth (CD), and serum cytokine levels of TNF-α, IFNγ, IL-1β, IL-6, IL-4, IL-10, IL-13, and IL-17 were also assessed. Results No weight loss was found in the SCID control group. Mean weight loss of 10.63?±?0.87% was noted by day five in 5-FU group without probiotics but it was only 6.2?±?0.43% if mice were given Lcr35 (p??0.01) and 7.1?±?1.80% (p??0.01) if they were given LaBi. Diarrhea score of 5-FU group without probiotics was 2.0?±?0.0 by day five, which dropped to 1.33?±?0.17 (p??0.05) and 1.42?±?0.24 (p??0.05) with Lcr35 and LaBi, respectively. Average VH significantly decreased and CD significantly increased in SCID mice given 5-FU. With probiotics, average CD improved (p??0.05) while VH lengthened as well. Besides IL-13, all cytokine levels increased in 5-FU SCID mice. Both Lcr35 and LaBi significantly inhibited serum cytokines ( p ??0.05). No probiotic strains were detected in blood cultures of any mice. Conclusion Using SCID/NOD mice as a novel model for 5-FU induced intestinal mucositis, we find that probiotics Lcr35 and LaBi do not lead to bacteremia, can improve diarrhea and body weight, can restore jejunal crypt depth, and significantly inhibit cytokines TNF-α, IL-1β, IFNγ, IL-6, IL-4, IL-10, and IL-17.
机译:背景对于化疗患者,肠粘膜炎是一种常见的并发症。以前,我们评估了口服益生菌对5-氟尿嘧啶(5-FU)诱导的BALB / c小鼠黏膜炎的有益作用。在这里,我们改用SCID / NOD小鼠模拟化疗患者的免疫缺陷:首先,评估益生菌补充剂的安全性,其次,确定对5-FU肠粘膜炎的益生菌作用。方法每天对36只SCID / NOD小鼠腹腔注射生理盐水(3个对照组)或5-FU(3个实验组),连续5天。每天给小鼠口服盐水,干酪乳杆菌多种鼠李糖(Lcr35,Antibiophilus ?,法国)或嗜酸乳杆菌和双歧双歧杆菌(LaBi,Infloran ?,意大利)的益生菌悬浮液。血,肝,脾和淋巴结组织样品通过培养和Q-PCR进行了益生菌易位评估。体重变化,腹泻评分,空肠绒毛高度(VH)和隐窝深度(CD)以及血清中TNF-α,IFNγ,IL-1β,IL-6,IL-4,IL-10,IL-13,还评估了IL-17。结果在SCID对照组中未发现体重减轻。在没有益生菌的5-FU组中,第5天的平均体重减轻了10.63±±0.87%,但是如果给小鼠施用Lcr35(p <0.01)和7.1±1.80,则仅为6.2±0.43%。 %(p?<?0.01)(如果给予LaBi)。到第5天时,没有益生菌的5-FU组的腹泻评分为2.0±±0.0,而Lcr35和Lcr分别降至1.33±0.17(p <0.05)和1.42±0.24(p <0.05)。 LaBi。给予5-FU的SCID小鼠的平均VH显着降低,CD显着增加。使用益生菌,平均CD改善(p <0.05),同时VH也延长。除IL-13外,5-FU SCID小鼠的所有细胞因子水平均升高。 Lcr35和LaBi均显着抑制血清细胞因子(p <0.05)。在任何小鼠的血液培养物中均未检测到益生菌菌株。结论使用SCID / NOD小鼠作为5-FU致肠黏膜炎的新型模型,我们发现益生菌Lcr35和LaBi不会导致菌血症,可以改善腹泻和体重,可以恢复空肠隐窝深度,并显着抑制细胞因子TNF-α α,IL-1β,IFNγ,IL-6,IL-4,IL-10和IL-17。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号